article
How GPCR agonists, including antibodies, are shaping the future of metabolic care
Find out how Confo Therapeutics is overcoming challenges in GPCR drug development to create next-gen therapies for metabolic diseases.
List view / Grid view
Pharmacology
podcasts
Leveraging “omics” for novel microbiome drug concepts
Listen to this episode to discover how microbiomics is being leveraged to translate gut microbiome findings into new therapeutic options.
article
Women in STEM with Kristina Torfgard
Introducing Kristina Torfgard! Holding a PhD in Clinical Pharmacology, she has over 30 years’ experience in drug development and is currently CEO of IRLAB Therapeutics.
podcasts
Combatting disease with antibody drug conjugates
Tune into this episode where we investigate how antibody drug conjugates can be optimised, as well as the future of the field.
article
Developing the next generation of antibody drug conjugates
In this Q&A, Léo Marx, Medicinal Chemistry Project Manager at Debiopharm, details how the therapeutic window of ADCs can be impacted, how we can overcome the challenges associated with achieving site-specific bioconjugation, and other essential considerations for optimising ADC performance.
news
China approves IND application for Everest Medicines novel BTK inhibitor
The Chinese National Medical Products Administration has approved a Phase Ib study of Everest Medicines' EVER001, for potential treatment of glomerular diseases.
news
Takeda enters agreement with F-star Therapeutics to license bispecific antibody
F-star Therapeutics has announced a licence agreement with Takeda for a novel next-generation immuno-oncology bispecific antibody.
news
Researchers create weakened version of SARS-CoV-2 that does not cause illness or death
Scientists have received approval to work with a weakened, non-harmful version of SARS-CoV-2 in biosafety level 2 laboratories, which makes it more efficient to study the virus, and to identify new treatments.
news
Five SARS-CoV-2 antiviral candidates revealed in drug screening study
Using virtual screening, researchers have discovered several natural compounds that could inhibit the SARS-CoV-2 main protease.
news
Alterity’s ATH434 improves Parkinson’s-related gastrointestinal dysfunction
ATH434 reversed some of the gastrointestinal damage to the enteric nervous system associated with Parkinson's disease in a pre-clinical study.
news
PANACEA consortium to increase global access to NMR spectroscopy
The Pan-European Solid-State NMR Infrastructure for Chemistry-Enabling Access will offer researchers access to over 30 NMR spectrometers.
news
Psilocybin spurs growth of neural connections lost in depression in vivo
Research from Yale University has shown that psilocybin, given to mice, triggered an increase in connections between neurons.
news
Antidepressants inhibit growth of pancreatic and colon cancers in mice
Scientists have discovered that approved antidepressant drugs cause immune cells to recognise and eliminate tumour cells in mouse models.
news
NINDS awards Sinopia $3.3m for development of Parkinson’s drug candidate
Sinopia has been awarded a $3.3 million Fast-Track SBIR grant to fund the study for its small molecule candidate for Parkinson’s disease.
news
Promising pre-clinical data announced for Parkinson’s drug
Stealth BioTherapeutics reported positive data from a pre-clinical study evaluating SBT-272 in a murine model of Parkinson's disease.